WO2023018810 - HETEROCYCLIC COMPOUNDS AND METHODS OF USE
National phase entry:
Publication Number
WO/2023/018810
Publication Date
16.02.2023
International Application No.
PCT/US2022/039969
International Filing Date
10.08.2022
Title **
[English]
HETEROCYCLIC COMPOUNDS AND METHODS OF USE
[French]
COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS D'UTILISATION
Applicants **
AMGEN INC.
Inventors
LANMAN, Brian Alan
ZHAO, Wei
WURZ, Ryan Paul
NAVARATNE, Primali
PETTUS, Liping
YAMANO, Michael M.
CHEN, Ning
RAHIMOFF, Rene
MANONI, Francesco
STELLWAGEN, John
Priority Data
63/231,543
10.08.2021
US
63/289,578
14.12.2021
US
63/299,667
14.01.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4240 | |
| EPO | Filing, Examination, Granting | 31494 | |
| Japan | Filing, Examination, Granting | 3118 | |
| South Korea | Filing, Examination, Granting | 4117 | |
| USA | Filing, Examination, Granting | 12010 |
Total:
54,979
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides compounds useful for the inhibition of KRAS G12D. The compounds have a general Formula I: wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.[French]
La présente invention concerne des composés utiles pour l'inhibition de KRAS G12D. Les composés ont une formule générale I, les variables de la formule I étant définies dans la description. L'invention concerne également des compositions pharmaceutiques comprenant les composés, des utilisations des composés et des compositions pour traiter par exemple le cancer.